secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2024-08-19T23:59:59+00:00
Accession:  0000950170-24-098289
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kineta reopens VISTA-101 trial; 30 of 39 patients enrolled; KVA12123 safe
-------------------------------------------------------------------------

- Kineta reopened enrollment in VISTA-101 Phase 1/2 trial for KVA12123; expects full enrollment by end of 2024.
- 30 of projected 39 patients enrolled; cleared 5th of 6 monotherapy dose levels and 2 of 4 combination cohorts.
- Initial results showed partial response and stable disease in combo cohorts; durable stable disease in monotherapy.
- KVA12123 demonstrated no dose-limiting toxicities and no CRS-associated cytokines at any dose level.
- TuHURA has exclusive right to negotiate acquisition until Oct 1, 2024 (extendable) after $5M nonrefundable payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024098289/0000950170-24-098289-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024098289/ktra-20240819.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-098289

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer